Open AccessSecond-line Therapy with TKIs Improves Time to Progression for Refractory Thyroid Cancer
Author(s) -
Mark Fuerst
Publication year - 2013
Publication title -
oncology times
Language(s) - English
Resource type - Journals
eISSN - 1548-4688
pISSN - 0276-2234
DOI - 10.1097/01.cot.0000435379.90267.88
Subject(s) - sorafenib , medicine , sunitinib , thyroid cancer , oncology , refractory (planetary science) , progression free survival , clinical endpoint , cancer , clinical trial , targeted therapy , follicular thyroid cancer , papillary thyroid cancer , chemotherapy , hepatocellular carcinoma , physics , astrobiology